Фильтр

Лекарственные препараты : обзор инвестиций и аналитика

(Данные обновляются)
Подотрасли: Лекарственные препараты - 219 (······)
Регионы: Московская область - 33 (······) , Москва - 21 (······) , Санкт-Петербург - 19 (······) , Калужская область - 10 (······) , Брянская область - 2 (······) , Кировская область - 4 (······) , Башкортостан - 2 (······) , Краснодарский край - 4 (······) , Мурманская область - 1 (······) Показать все...
Другие страны: Беларусь - 15 (······) , Узбекистан - 27 (······) , Казахстан - 17 (······) , Кыргызстан - 4 (······) , Азербайджан - 2 (······) , Таджикистан - 2 (······)
Период: 2021 - 2031
Холдинги:  83
Проектов по фильтру:  219 (684,6 млрд руб.)

Лекарственные препараты относятся к фармацевтической промышленности и представляют собой дозированные, готовые к применению средства в определенной лекарственной форме, применяемые для профилактики, диагностики, лечения заболеваний.                                             

По состоянию на 26 февраля 2025 года в отрасли насчитывается 146 проектов с объемом инвестиций в 402,3 млрд рублей. Интересантами реализации проектов выступают 67 крупных структур, которые занимаются финансированием, проектированием и строительством предприятий отрасли.

Более 90% инвестиций в отрасли осуществляется частными компаниями. Концерн «Россиум» ведет предпроектные проработки инициативы фармацевтического производства в Зеленограде Московской области. Объем инвестиций составит около 44 млрд рублей. Биотехнологический комплекс будет размещен на площадке «Алабушево» особой экономической зоны ТВТ «Технополис Москва». Возможности комплекса позволят производить лекарственные препараты по 13 международным непатентованным наименованиям для лечения онкологических, генетических и редких заболеваний. Ввод в эксплуатацию запланирован на 2028 год. Предприятие войдет в фармацевтический кластер, который формируется на базе ОЭЗ «Технополис Москва». Участники кластера располагаются на двух площадках: «Алабушево» и «Печатники».

Инвестиции в проекты по годам

.. ...................... .................. ........ ...... .. .............. ............................ .................... .......... ................................ .. ................ .... .......... ..... ........ ............. ...... ...................... ............ ................ .... .... ... ... .................... ................ .... ........ ............. .......... .... .... ... ............................ .................... .................... .................... .. .............. .... ..... .. ...... .... ... ........ ............. ................ .......................... .......... .................... .......... .................... .. .... ... ... .................... .................... .... ..... .... .................. .... .................. .... ... ...... .................... .......... .................. .......... .. ........................ .......................... ................ ........................ .. ............................... .....

.. .............. ...................... .............. .... .................... .............. .... ...................... ................ ...................... .... .. .............. .................... .......... ..... ........ ............ ...... ... .................. ................................ .. ...................... .... . ....... ............ .......... .......... ................ ............................. ..... .. .............. .......................... ..... .................... ................ .. .......... ...... .... ........ ............. .............. ............ .............. ...................... .... .. .............. .................... .... ........ ............ ....... ..................... .. .............. .... .......... .. .............. ............................ .....................

..

Структура по инвесторам

................ .................. .... ..................... .............. ................ .................. .. ................ ................ .................... ... ........ ............. .... ...... . ............ .... .......... .... ........ ............ .... .... ............................ ..................... .......... ................ .... ........ .............. ................ ................... ............................ .................... .... ........ ............ ....... .. . ................. ............ .......... ................ ............ ................ ........................... .............. .................. .. ................ .... .......... .... ........ ............ ....... ................ ........ .................. ................ ................ .. ....................... .... .............. .................... .... . .............. .................... .. ........ ............ .... .. .... ........ ............ ...... ............................. ....... .................... ................ .. .............. ............................ .....................

..................... ...... .... ........ .................... ................ .. .................... .................... .......... ...................... .. ................ .... ..... ........ ............ ... ...... ..... .... .......... ........ .................... .. .............................. ............... .......... .......... .. ................................ ...... .... ........ ............ ................ .... ................. .... ................ .. ................. ............... .................. ................ .. .............. ............................ .....................

..

Проекты на активной стадии

.... .................... ...... ................ ...................... .. .......... .......................... .................... .......... ................................ ...... .................... .. ............ .. ................ ............... .. ............ .... ... .................... ................ .. .............. .................. ...... ........ ............... .......... .. .............. .... ............ .... ... ................................ ...................... .... ... ........ .............. .. ................ ...... ........ .............. .. .......... ............... .. ...... .... ... .................... .................... .... .... .... ...... ........ .............. .... .................. .. .............. .... ... ........... .. ........ .... ... .................. ............ .................................. .. ............... .................. ........................ ....................... .............. .................. ...... ........ ............... ...... .............. .. ........ .... ................ .... ... ...................... ...................... .......... ................ .. .............. .... ..... .......... .............................. .................... .. .............. .... ... ................................ .. ........................... .... ... .......... ....................... .................. ........................ .................... .. ... ........ ....... .. .......... ............... .................... .. ............ .... ... ................ ...... .....................

................ .................... ................ ................ .............. ............................ .................... .... .................... ...... .......... .......................... .. .................. ........... .. ........ .... ... ... .... . ............... .. .............. .... ... ... .... . .............. .. .. .............. .... ... ... .... . .............. ............................. .. .......... .... ............ .................... ................ .... .... .. ... ..... .. ............ .... ... .... ... ..... .. ............ .... ...

.... .................. .... .............. .... ........ .. .............. .......................... ... ................ ................ .................... ...... ........ ............... ...... .... ... ...... .............. ............. ...... ........................... ..................... .. .................. ................ .... ................ ............ ....... ................................. .. .............. ............................ .....................

..

Структура проектов по стадиям

.. .............. .................... ................ .... .............. .................... .......... ................. ...... .... ................ .............. .............................. ............................ ....................... ................................. ...................... .. ............................. ............................... ............................. .................. ... ................ .............. ............................ .................... .......... .................... ..... ........ ............. .... ...... .. ............ .... .................... .. ............... .... .......... ..... ........ ............ .................. .... ............ .............. ..................... .. .. ................ ..... .... .... ........ ............ ... ........................... .... ............ ...................... .. ............................. .............................. .. ............................ .................. ... ................ ...... .. ............ .......... .................... ... ........ .............

...... ........ ... ... ............. .................... .................... ................ .................... ..... ........ ............ ..................... .................... .... ................................ ................ ... ................ .................. .... ........................ ................ ................................ .................... .... .. ........ ............. ............ .................. .... ............ ........................... .. .................... .................. .............. ..................... ................... .................... .... .............. .. .............. ............................ .....................

..

Структура инвестиций по регионам

.................. .................... .... ................ ........................... ...... .................. .... .................................. .. .......... .......................... .................... ................ .................... .............. ... .... ...... .................... ..... .................... .................... .......... ...... .... ........ ............ .. .. ................. .... ............ .......... ............ ... .. .. ................ .......................... .... ........ ............ ........ .... .................... ............................... .................... .. .................... ................ .......... ............ .... ........ ............ ...... .... .. .................. .............. ...................... . .............. .................... .... ........ ............ ....... ................ ........ .................. ............... .... .............. .................... . .............. .................... .... ........ ............ .......

.. ........ ................ .......................... ... ........ ................................ .. .............. ...... ..... ........ ............ .. .. ............... .......... .. .. ........................ ................ .......... ...................... ..... ........ ............ .................... ... ..... .... ............ ...................... ............ ............... ................... .................... .... ................ .... .. .............. ............................ .....................



Новости холдингов отрасли
  • 04.04.2025

    Указом Президента Российской Федерации ООО «Фармирус» назначено управляющим 100%-м пакетом акций АО «Нижфарм».

    Комментарий ПКР: это решение усиливает контроль над стратегически важными российскими предприятиями и имеет долгосрочные перспективы для развития фармацевтической отрасли России.

  • 14.03.2025
    ···· ······················-··········: ······················ ·············· ········ ········ ···· ························································.·················································· ···························· ···································· ················ ········ ···· ························································.·············································· ···················· ···················································· ························································.·························································· ·················································· ·· ·················· ···· ························································.······················································ ·················· ································ ························ ···· ······················ ·············· ·················· ················ ···· ························································.······················································ ·················· ································ ·· ···· ························································.·············································· ···················· ·························································· ···· ······················-··········: ········································ ········ ······ ·············· ·········· ················ ·· ···················· ·············· ························ ················ ···· ·········· ·· ························ ················ ·················· ······················ ···················· ························ ··························
  • 22.10.2024
    ···· ······················-··········: ························ ························································.···················································· ···················································· ·················· ········ ·········· ·················· ················ ···· ························································.························································ ························ ······································ ···················· ································ ·········· ·· ································ ······················ ·· ·········································· ···· ······················-··········: ·········································· ········ ························ ···· ························································.························································ ························ ···································· ·················· ······ ···· ························································.···················································· ···················································· ·········· ······················ ···· ································ ············ ·············· ············ ·········· ·········· ···························· ·········· ······ ···························· ·············· ·· ···················· ·············· ···· ·········· ·························· ······························
  • 28.06.2023
    ······················ ·················· ············ ···· ···················· ·························· ···································· ·· ···························· ···· ························································.····························-··········-···························· ························ ················ ······ ·········· ·········· ·· ···· ························································.·················································································· ·········· ···· ························································.·········································································· ················ ································ ···· ······················ ························ ······ ························ ························ ·· ·············· ·· ················ ·················· ···· ·· ········ ········ ·················· ······ ·········· ·············· ·· ···················· ······················ ············ ···· ·········· ···················· ·················· ·· ······················ ···························· ········ ················ ······ ························································.·············································································· ················ ···· ·············· ················ ···· ························································.····························-··········-················································
  • 28.02.2023
    ········ ·············· ········ ········ ················ ················ ···· ························································.·············································· ························ ···· ························································.············································································ ·········· ···················· ·········· ·········· ·· ···· ························································.························································ ······················ ······ ······················ ·················· ······························ ·· ···· ························································.······································-·························· ·················· ···························· ······ ········ ········ ·· ············ ·············· ···· ························································.·································································· ·········· ········ ···················· ·························· ···················· ···· ························································.················································································ ···························· ········ ···· ························································.························································ ···················· ·················· ························································.························································ ···················· ···················· ·· ············ ················ ···· ························································.············································································
  • 03.10.2022
    ················ ·································· ························································.·········································································· ·············· ········ ·········· ·························· ············ ······ ························································.·········································································· ······ ······················ ·· ···· ················ ·· ·············· ·········· ······················ ········································ ················ ···················································· ········ ······ ························································.·········································································· ················ ·· ·············· ················ ···· ························································.··································································································
  • 01.09.2022
    ········ ················-··················-·················· ························································.···························································································· ·············· ···················· ·········· ········ ·········· ························ ···· ························································.······································································ ·· ························ ·················· ·············· ················ ·············· ·············· ········ ·· ················ ············ ·········· ·········· ················ ·· ·············· ···· ·············· ·· ·············· ········ ········ ······················ ·············· ···· ··········-···· ···························· ················ ·················································· ········ ······ ························································.···································································· ················ ·· ············ ················ ···· ························································.····················································································································
  • 29.08.2022
    ·································· ·············· ···· ························································.······································-···························· ······················ ·············· ·· ···· ·············· ·············· ······················ ·············· ········ ·········· ················ ·········· ······························ ················ ······················ ······ ······································ ············································ ···························· ········ ······················ ···················· ···· ························································.······································-···························· ························ ·· ········ ·················· ················ ········ ······ ················ ································
  • 21.07.2022
    ········ ···················· ················ ·········· ·············· ···· ························································.·················································· ······························ ······························································ ······ ······················ ························ ················ ················ ················ ···· ································ ·············· ·· ·········· ······ ······ ···················· ···························· ········ ············ ·········· ·············· ···· ························································.····························································································
  • 04.02.2022
    ································ ·············· ···· ························································.·································································· ············ ············ ···· ·············· ························ ············ ·········· ···················· ················ ········ ···· ························································.·············································································· ···· ············ ········ ················ ················ ·············· ········ ·················· ···· ························································.············································································ ············ ···· ·········· ············ ················ ········ ·· ············ ·········· ···· ························································.····································-········································ ·· ················ ············ ············ ·············· ···················· ················ ·· ······································ ···························· ········ ···· ························································.············································································ ················ ·· ············ ················ ···· ························································.·································································· ·· ················ ································

  • Топ крупнейших групп проектов в отрасли "Лекарственные препараты"

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Проекты в отрасли "Лекарственные препараты"

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Инвестиции в проекты по годам в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** В зависимости от примененных фильтров по умолчанию может выводиться ТОП-8 категорий. Для выбора остальных категорий воспользуйтесь легендой под графиком

    Структура инвестиций по подотраслям по годам в отрасли "Лекарственные препараты" (Данные обновляются)

    Ввод в эксплуатацию (и прогноз ввода) проектов по годам в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтр учитывает все стадии проектов, кроме «приостановлен».

    Структура инвестиций по регионам РФ в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП регионов. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Структура инвестиций по ФО в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Структура инвестиций по видам собственности в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Структура инвестиций по стадиям в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры выстроены от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Структура инвестиций по размерности проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Инвестиционная активность за 12 месяцев в отрасли "Лекарственные препараты" (Данные обновляются)

    Количество и стоимость проектов на активной стадии (без приостановленных) в отрасли "Лекарственные препараты" (Данные обновляются)

    Количество и стоимость проектов на стадии Приостановлен (накопительным итогом) в отрасли "Лекарственные препараты" (Данные обновляются)

    Динамика добавления новых проектов на платформу в отрасли "Лекарственные препараты" (Данные обновляются)

    Динамика ввода проектов в эксплуатацию в отрасли "Лекарственные препараты" (Данные обновляются)

    Динамика приостановки проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    Приостановка проектов по месяцам в отрасли "Лекарственные препараты" (Данные обновляются)

    Динамика выхода проектов из приостановки в отрасли "Лекарственные препараты" (Данные обновляются)

    Динамика отмены проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    Топ инвесторов проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Крупные инвесторы проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП инвесторов. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Топ генеральных проектировщиков проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Генеральные проектировщики в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП генпроектировщиков. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Топ генеральных подрядчиков проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию

    Генеральные подрядчики в отрасли "Лекарственные препараты" (Данные обновляются)

    * По умолчанию фильтры учитывают: только активные стадии проектов; от самого раннего срока начала строительства проекта по самый поздний срок предполагаемого ввода в эксплуатацию
    ** По умолчанию выводится ТОП генподрядчиков. Для выбора остальных категорий воспользуйтесь легендой слева от графика

    Структура инвестиций в иностранной собственности без российских бенефициаров в отрасли "Лекарственные препараты" (Данные обновляются)

    Российские инвестиции в другие страны в отрасли "Лекарственные препараты" (Данные обновляются)

    Площадь объектов по ФО в отрасли "Лекарственные препараты" (Данные обновляются)

    Площадь участков проектов по ФО в отрасли "Лекарственные препараты" (Данные обновляются)

    Совместные инвестиции России и в отрасли "Лекарственные препараты" (Данные обновляются)

    Интеграция через технологии и строительство (Генпроектировщик, Генподрядчик, Проектировщик, Субподрядчик) Территория – Россия, исполнители в отрасли "Лекарственные препараты" (Данные обновляются)

    Интеграция через технологии и строительство (Генпроектировщик, Генподрядчик, Проектировщик, Субподрядчик) Территория в отрасли "Лекарственные препараты", исполнители – Россия (Данные обновляются)

    Основные холдинги-инвесторы в отрасли "Лекарственные препараты" (Данные обновляются)

    Основные холдинги-инвесторы в отрасли "Лекарственные препараты" (Данные обновляются)

    Динамика выручки холдингов инвесторов отрасли в отрасли "Лекарственные препараты" (Данные обновляются)

    Инвестиции в проекты по годам в отрасли "Лекарственные препараты" (Данные обновляются)

    Крупные инвесторы проектов в отрасли "Лекарственные препараты" (Данные обновляются)

    Генеральные проектировщики в отрасли "Лекарственные препараты" (Данные обновляются)

    Генеральные подрядчики в отрасли "Лекарственные препараты" (Данные обновляются)

    Структура инвестиций по стадиям в отрасли "Лекарственные препараты" (Данные обновляются)

    Структура инвестиций по видам собственности в отрасли "Лекарственные препараты" (Данные обновляются)

    Структура инвестиций по регионам в отрасли "Лекарственные препараты" (Данные обновляются)

    Проекты по параметру "Вид контракта" в подотрасли "Лекарственные препараты" (Данные обновляются)

    "Вид контракта" по ФО в подотрасли "Лекарственные препараты" (Данные обновляются)

    в отрасли "Лекарственные препараты" (Данные обновляются)

    в отрасли "Лекарственные препараты" (Данные обновляются)

    в отрасли "Лекарственные препараты" (Данные обновляются)

    в отрасли "Лекарственные препараты" (Данные обновляются)

    Используемые материалы в отрасли "Лекарственные препараты" (Данные обновляются)

     

    Графики по Вашему запросу отсутствуют.

    Вы можете изменить настройки фильтра или сбросить все его текущие настройки.
    Показать